�UroToday.com - Dr. Arto Salonen and Finnish colleagues compared intermittent androgen deprivation (IAD) to continuous androgen deprivation (CAD) in 856 patients with locally advanced or metastatic prostate crab (CaP) treated at 27 clinics in Finland. This report represents an meantime analysis of their information.
The patients were accrued between 1997 and 2003 and had a life expectancy of at least 12 months. A 24 week run in of continuous LHRH agonist therapy preceded randomization for those who had a PSA decrease to
Mean patient age was 72 age and mean PSA at entry was 383ng/ml. Patients had phase T3 tumors (61%) and stage T4 tumors (29%). A total of 564 men completed the row period and 279 were randomized to IAD and 285 to CAD. PSA, alkaline phosphatase, proportion of T4 tumors, poorly differentiated tumors, metastatic disease, and skeletal hot spots among patients with M1 disease were significantly higher in the IAD group. Baseline testosterone was not significant in the analysis.
A significant proportion of patients with the most aggressive and advanced CaP did not respond to androgen deprivation therapy. The investigators concluded that IAD appears feasible for patients with locally advanced, hormone sensitive CaP. A low terminus ad quem of testosterone at baseline did not select for IAD or CAD. Patients with advanced CaP, with a high PSA, alkalic phosphatase and metastatic disease, with more than 5 skeletal hot spots, did not show adequate biochemical response to ADT. Thus, they ar not good candidates for IAD and other modalities should be considered.
Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL
J Urol. 2008 Jul 15. Epub ahead of print.
doi:10.1016/j.juro.2008.05.009
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content written by planetary urology key opinion leaders actively engaged in clinical practice.
To access the modish urology news releases from UroToday, go to:
www.urotoday.com
Copyright � 2008 - UroToday
More info
